Healthy Mind

Healthy Mind occupies a focused position at the intersection of medical virtual reality, digital therapeutics, and anxiety and pain management. Its differentiation is the application of immersive VR in specific care environments rather than positioning VR solely as a consumer relaxation or general wellness product. The company describes use cases spanning emergency care, chemotherapy, dialysis, anesthesia, rehabilitation, and postoperative recovery, giving it a broader clinical workflow scope than a single-condition therapy. Its portfolio also extends into neurofeedback through Neuromind and workplace well-being through the QVT VR Solution, creating multiple potential customer segments but also increasing the need for clear regulatory and clinical positioning. Relative to broad digital mental-health platforms, Healthy Mind’s distinct angle is its headset-based therapeutic delivery and combination of immersive environments, hypnosis, and relaxation techniques. Its small disclosed team and €1 million Seed financing indicate an early-stage position, with market strength likely dependent on evidence generation, healthcare procurement, and repeatable deployment across institutions.

Healthy Mind’s trajectory shows a progression from founding in 2017 to a specialized therapeutic-VR business with three identifiable product lines. The Nov 22, 2017 founding date and Timothée Cabanne’s CEO and co-founder appointment in December 2017 mark the initial company formation. The €1 million Seed round announced on Feb 9, 2022, led by Axeltim, represents the main disclosed financing inflection point and likely supported product development and commercialization. Hiring signals indicate expansion of 10 people during 2022 and 20 more in a later period, but the available employee classification still places the company in the 1–10 employee range, creating uncertainty about whether those additions were temporary, cumulative, or related to broader teams. Product breadth has expanded across procedural anxiety and pain relief, chronic-disease neurofeedback, and workplace well-being. There is no reliable evidence here of later financing, acquisitions, major launches, or revenue scale. Future growth appears tied to clinical validation, regulatory adoption, institutional partnerships, and converting a multi-use product portfolio into repeatable healthcare deployments.